| stavudine / Generic mfg. |
NCT00001063: The Effectiveness of Three Drug Combinations in HIV-Infected Patients Who Have Taken Zidovudine for More Than 12 Weeks |
|
|
| Completed | 2 | 200 | US | Stavudine, Zidovudine, Didanosine | National Institute of Allergy and Infectious Diseases (NIAID), Bristol-Myers Squibb | HIV Infections | | 11/97 | | |
NCT00000838: Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or Didanosine |
|
|
| Completed | 2 | 256 | US | Lamivudine, Stavudine, Zidovudine, Didanosine | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | | 03/98 | | |
NCT00000789: A Randomized, Comparative Trial of Zidovudine (AZT) Versus 2',3'-Didehydro-3'-Deoxythymidine (Stavudine; d4T) in Children With HIV Infection |
|
|
| Completed | 2 | 230 | US | Stavudine, Zidovudine | National Institute of Allergy and Infectious Diseases (NIAID), Glaxo Wellcome, Bristol-Myers Squibb | HIV Infections | | 07/98 | | |
NCT00000851: Comparison of Stavudine Used Alone or in Combination With Didanosine in HIV-Infected Children |
|
|
| Completed | 2 | 198 | US | Stavudine, Didanosine | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | | 10/98 | | |
NCT00000882: Virologic and Immunologic Activity of Continued Lamivudine (3TC) vs Delavirdine (DLV) in Combination With Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Subjects |
|
|
| Completed | 2 | 300 | US | Indinavir sulfate, Delavirdine mesylate, Lamivudine, Stavudine, Zidovudine | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 05/99 | | | |
NCT00000939: A Study to Compare the Effectiveness of Different Anti-HIV Drug Regimens in Keeping Levels of HIV in the Blood as Low as Possible |
|
|
| Completed | 2 | 150 | US | Hydroxyurea, Efavirenz, Stavudine, Didanosine | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | | 01/00 | | |
NCT02249130: Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir |
|
|
| Completed | 2 | 18 | US, RoW | Tipranavir (TPV), Ritonavir (RTV), Delavirdine (DLV), Zidovudine (ZDV), Lamivudine (3TC), Stavudine (d4T) | Boehringer Ingelheim | HIV Infections | 04/00 | | | |
NCT00000924: A Study to Compare Two Different Anti-HIV Drug Regimens |
|
|
| Completed | 2 | 120 | US | Ritonavir, Nelfinavir mesylate, Nevirapine, Stavudine, Didanosine | National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | HIV Infections | | 06/01 | | |
NCT00001688: A Pilot Study of the Immunologic Reconstitution in HIV-1 Infected Children Receiving Highly Active Antiretroviral Therapy With Combination Ritonavir, Nevirapine and Stavudine |
|
|
| Completed | 2 | 25 | US | Ritonavir, Nevirapine, Stavudine | National Cancer Institute (NCI) | HIV Infection | | 11/01 | | |
NCT00002240: Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs |
|
|
| Completed | 2 | | US, Canada | Atazanavir, Nelfinavir mesylate, Stavudine, Didanosine | Bristol-Myers Squibb | HIV Infections | 12/01 | 12/01 | | |
NCT00001122: A Study of an Adherence Plan to Help HIV-Positive Patients Take Their First Anti-HIV Medications Correctly |
|
|
| Completed | 2 | 74 | US | Nelfinavir mesylate, Efavirenz, Stavudine, Didanosine | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 10/03 | | | |
NCT00270556: Phase II Comparator Study of Substitution of Tenofovir or Abacavir Receiving Thymidine Analogue as Part of HAART. |
|
|
| Completed | 2 | 100 | Europe | tenofovir disoproxil fumarate, Abacavir | Gilead Sciences | HIV | | 10/04 | | |
RAVE, NCT00647946: Study to Evaluate Changes in Limb Fat When Switching From a Thymidine Analogue |
|
|
| Completed | 2 | 100 | Europe | tenofovir DF, abacavir 300mg twice daily | Gilead Sciences | Lipodystrophy | 10/04 | 02/06 | | |
| Completed | 2 | 90 | US | Lopinavir/Ritonavir, Emtricitabine, Stavudine | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | | 04/05 | | |
NCT00002412: A Study of MKC-442 in Combination With Other Anti-HIV Drugs |
|
|
| Completed | 2 | | US | Emivirine, Hydroxyurea, Stavudine, Didanosine | Triangle Pharmaceuticals | HIV Infections | | | | |
NCT00002225: A Study of Efavirenz in Combination With Stavudine and Didanosine |
|
|
| Completed | 2 | 60 | US | Efavirenz, Stavudine, Didanosine | Dupont Merck | HIV Infections | | | | |
NCT00017992: Emtricitabine Given Once A Day With Other Anti-HIV Drugs in Children With HIV |
|
|
| Unknown status | 2 | 100 | US, RoW | Lopinavir/Ritonavir, Emtricitabine, Stavudine | Triangle Pharmaceuticals | HIV Infections | | | | |
NCT00002442: A Study to Compare the Safety and Effectiveness of Two Dosing Schedules of Lamivudine in Combination With Two Other Anti-HIV Drugs |
|
|
| Completed | 2 | | US | Indinavir sulfate, Nelfinavir mesylate, Lamivudine, Stavudine | Glaxo Wellcome | HIV Infections | | | | |
NCT00036452: A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation |
|
|
| Completed | 2 | 402 | US, RoW | lopinavir/ritonavir, emtricitabine, stavudine, tenofovir DF | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | | 01/06 | | |
NCT00007202: Safety and Effectiveness of a Three-Drug Combination Treatment for Recently Infected or Converted HIV Patients |
|
|
| Completed | 2 | 55 | US, RoW | Atazanavir, Stavudine, Didanosine | National Institute of Allergy and Infectious Diseases (NIAID), Bristol-Myers Squibb | HIV Infections | | 10/06 | | |
NCT00002420: The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors |
|
|
| Terminated | 2 | 25 | US | Emivirine, Hydroxyurea, Delavirdine mesylate, Stavudine, Didanosine | Bristol-Myers Squibb, Pharmacia and Upjohn, Triangle Pharmaceuticals | HIV Infections | | | | |
NCT00002418: The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors |
|
|
| Terminated | 2 | 25 | US | Emivirine, Hydroxyurea, Nevirapine, Stavudine, Didanosine | Bristol-Myers Squibb, Boehringer Ingelheim, Triangle Pharmaceuticals | HIV Infections | | | | |
2010-021651-79: Studio degli effetti immuno-virologici dell’interruzione di Maraviroc nei pazienti che stanno fallendo un regime contenente Maraviroc Viro-Immunologic Effects of Interrupting Maraviroc in Patients Failing a Maraviroc-containing Antiretroviral Treatment (The Maraviroc Short-Stop Study) |
|
|
| Terminated | 2 | 30 | Europe | Coated tablet, Capsule, hard, Film-coated tablet, Gastro-resistant capsule, hard, Tablet, Capsule, soft, CELSENTRI*60CPR RIV 150MG, EMTRIVA*1FL 30CPS 200MG, COMBIVIR*60CPR RIV 150MG+300MG, CELSENTRI*60CPR RIV 300MG, CELSENTRI*90CPR RIV 300MG, ATRIPLA*30CPR RIV600+200+245MG, EPIVIR*BLIST 30CPR RIV 300MG, KIVEXA*FL 30CPR RIV 600MG+300M, RETROVIR*60CPR 300MG, TRUVADA*30CPR RIV 200MG/245MG, VIDEX*30CPS GASTR 400MG, VIREAD*30CPR 245MG, ZERIT*56CPS 30MG, ZERIT*56CPS 40MG, INTELENCE*FL 120CPR 100MG, ZIAGEN*6BLISTER 10CPR 300MG, VIRAMUNE*60CPR 200MG, SUSTIVA*30CPR RIV 600MG BLIST, APTIVUS*FL 120CPS MOLLI 250MG, INVIRASE*FL 120CPR RIV 500MG, KALETRA*120CPR RIV 200MG+50MG, PREZISTA*120CPR RIV 300MG, REYATAZ*FL 60CPS 200MG, NORVIR*4FL 84CPS MOLLI 100MG, TELZIR*1FL 60CPR RIV 700MG, ISENTRESS*FL 60CPR RIV 400MG | FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR | patients affected by HIV in stable treatment with Maraviroc from at least 6 months pazienti adulti affetti da HIV in terapia stabile con Maraviroc da almeno 6 mesi, Diseases [C] - Virus Diseases [C02] | | | | |
NCT00471614: Effects of Uridine Supplementation on Metabolic Side Effects of Stavudine and Zidovudine |
|
|
| Completed | 2 | 3 | US | NucleomaxX (contains uridine) | National Center for Complementary and Integrative Health (NCCIH) | HIV Infections, Insulin Resistance, Hyperlactatemia | 01/12 | 01/12 | | |
NCT00006339: Safety and Effectiveness of an Anti-HIV Drug Combination With and Without Hydroxyurea in Patients With Early HIV Infection |
|
|
| Withdrawn | 2 | 0 | NA | Indinavir sulfate, Ritonavir, Hydroxyurea, Stavudine, Didanosine | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | | | | |
NCT00000822: A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells |
|
|
| Completed | 1/2 | 46 | US | Ritonavir, gp160 Vaccine (Immuno-AG), Stavudine, Didanosine | National Institute of Allergy and Infectious Diseases (NIAID), Bristol-Myers Squibb, Immuno-US | HIV Infections | | 05/99 | | |
NCT00000878: A Study to Evaluate the Safety and Tolerance of Stavudine (d4T) in Combination With Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants |
|
|
| Completed | 1/2 | 26 | US | Lamivudine, Stavudine, Zidovudine | National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | HIV Infections, Pregnancy | | 10/01 | | |
NCT00002427: Safety and Effectiveness of Combining Hydroxyurea (HU) With Didanosine (ddI) and Stavudine (d4T) for Treatment of HIV-Infected Adults |
|
|
| Completed | 1/2 | 225 | US | Hydroxyurea, Stavudine, Didanosine | Research Institute for Genetic and Human Therapy | HIV Infections | | | | |
NCT00312091: Drug Levels of Tablet and Liquid Forms of Lamivudine, Nevirapine, and Stavudine in HIV Infected Thai Children |
|
|
| Completed | 1/2 | 44 | RoW | Lamivudine, nevirapine, and stavudine fixed-dose tablet, GPO-Vir, d4T/3TC/NVP, Lamivudine, Nevirapine, Stavudine | National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), International Maternal Pediatric Adolescent AIDS Clinical Trials Group | HIV Infections | 09/08 | 09/08 | | |
